Novel cbg derivatives can reduce inflammation, pain and obesity

Natalya M. Kogan*, Yarden Lavi, Louise M. Topping, Richard O. Williams, Fiona E. McCann, Zhanna Yekhtin, Marc Feldmann, Ruth Gallily, Raphael Mechoulam

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Interest in CBG (cannabigerol) has been growing in the past few years, due to its anti-inflammatory properties and other therapeutic benefits. Here we report the synthesis of three new CBG derivatives (HUM-223, HUM-233 and HUM-234) and show them to possess anti-inflammatory and analgesic properties. In addition, unlike CBG, HUM-234 also prevents obesity in mice fed a high-fat diet (HFD). The metabolic state of the treated mice on HFD is significantly better than that of vehicle-treated mice, and their liver slices show significantly less steatosis than untreated HFD or CBG-treated ones from HFD mice. We believe that HUM-223, HUM-233 and HUM-234 have the potential for development as novel drug candidates for the treatment of inflammatory conditions, and in the case of HUM-234, potentially for obesity where there is a huge unmet need.

Original languageAmerican English
Article number5601
Issue number18
StatePublished - 15 Sep 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.


  • Anti-inflammatory
  • Cannabigerol
  • Cannabinoid
  • Obesity


Dive into the research topics of 'Novel cbg derivatives can reduce inflammation, pain and obesity'. Together they form a unique fingerprint.

Cite this